(1546171) Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort

Primary Author; Presenting Author(s)

• 

  Arnon P. Kater, MD, PhD

  Deputy Head, Clinical Hematologist, Head of Research Lab
  Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
  Amsterdam, Netherlands

  Slides

Co-Author(s)

• HE

  Herbert Eradat, MD

  David Geffen School of Medicine at UCLA
  Los Angeles, CA, United States
• 

  Carsten Utoft Niemann, MD, PhD

  Associate Professor, Chief Physician
  Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University
  Copenhagen, Denmark
• FO

  Fritz Offner, MD, PhD

  Universitair Ziekenhuis Gent
  Ghent, Belgium
• CP

  Christian Bjørn Poulsen, MD

  Zealand University Hospital
  Roskilde, Denmark
• TH

  Thor Høyer, MD

  Aalborg University Hospital
  Aalborg, Denmark
• MB

  Mar Bellido, MD, PhD

  University Medical Center Groningen and University of Groningen
  Groningen, Netherlands
• 

  Mazyar Shadman, MD, MPH

  Associate Professor of Medicine
  Fred Hutchinson Cancer Center / University of Washington School of Medicine
  Seattle, WA, United States
• TO

  Toshihiko Oki, MD, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• AK

  Alexandra Kuznetsova, PhD

  Genmab
  Copenhagen, Denmark
• MR

  Marcia Rios, MBA

  Genmab
  Princeton, NJ, United States
• RV

  Rebecca Valentin, MD, PhD

  Genmab
  Copenhagen, Denmark
• HB

  Hans Herluf Bentzen, MD

  Aarhus University Hospital
  Aarhus, Denmark